| 0.882 -0.011 (-1.21%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.47  |
1-year : | 1.77 |
| Resists | First : | 1.26 |
Second : | 1.51 |
| Pivot price | 0.94 |
|||
| Supports | First : | 0.83 | Second : | 0.69 |
| MAs | MA(5) : | 0.9 |
MA(20) : | 0.98 |
| MA(100) : | 0.91  |
MA(250) : | 0.93 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.4 |
D(3) : | 15.6 |
| RSI | RSI(14): 38.5 |
|||
| 52-week | High : | 4.75 | Low : | 0.24 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FEMY ] has closed above bottom band by 15.0%. Bollinger Bands are 80.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.9 - 0.91 | 0.91 - 0.91 |
| Low: | 0.86 - 0.86 | 0.86 - 0.87 |
| Close: | 0.87 - 0.88 | 0.88 - 0.89 |
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Wed, 29 Nov 2023
Should You Sell Femasys Inc (FEMY) Stock Wednesday Morning? - InvestorsObserver
Tue, 28 Nov 2023
Femasys: Ready To Turn The Corner (NASDAQ:FEMY) - Seeking Alpha
Tue, 28 Nov 2023
Femasys Inc (FEMY) Up 0.97% in Premarket Trading - InvestorsObserver
Fri, 24 Nov 2023
Should Medical Instruments & Supplies Stock Femasys Inc (FEMY) Be in Your Portfolio Friday? - InvestorsObserver
Thu, 16 Nov 2023
Femasys Inc (FEMY) Down 0.99% in Premarket Trading - InvestorsObserver
Wed, 15 Nov 2023
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 1.941e+007 (%) |
| Held by Institutions | 14.8 (%) |
| Shares Short | 1,290 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.253e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 670.1 % |
| Return on Equity (ttm) | -46.8 % |
| Qtrly Rev. Growth | 1.09e+006 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -0.69 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 12.37 |
| Price to Cash Flow | -4.81 |
| Dividend | 0 |
| Forward Dividend | 286740 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|